
Nikolay V Zhukov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6728286/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A spectrum of overgrowth syndromes associated with the <i>PIK3CA</i> mutation. Literature review. Russian Journal of Pediatric Hematology and Oncology, 2022, 9, 29-44.	0.3	2
2	MODERN POSSIBILITIES OF TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS). INFORMATION NOTICE. Pediatriia, 2022, 101, 234-235.	0.2	0
3	Nasopharyngeal carcinoma in children and adolescents: a literature review and our own data. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 66-77.	0.3	0
4	RENAL CELL CARCINOMA WITH SUCCINATE DEHYDROGENASE B DEFICIENCY IN A 15-YEAR-OLD BOY WITH SYNDROME OF HEREDITARY PHEOCHROMOCYTOMA AND PARAGANGLIOMA TYPE 4. Pediatriia, 2021, 100, 266-272.	0.2	0
5	INITIAL EXPERIENCE IN ESTIMATING TUMOR MUTATION BURDEN IN PEDIATRIC HEPATOCELLULAR CARCINOMA. Pediatriia, 2021, 100, 193-199.	0.2	0
6	A case report of lymphoepithelioma-like carcinoma in an adolescent. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 134-138.	0.3	0
7	Challenges in the diagnosis of growing teratoma syndrome: two case reports. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 126-132.	0.3	0
8	The transformation of aneurysmal bone cyst into telangiectatic osteosarcoma: the development of a second tumour or a wrong initial diagnosis?. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 150-157.	0.3	0
9	The prevention and treatment of chemotherapy-induced nausea and vomiting in children and adolescents receiving cancer treatment: the current status and possibilities for improvement. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 205-223.	0.3	2
10	Potentially Curative Targeted Therapy for Undifferentiated High-Grade Sarcoma Developing After Malignant Transformation of a <i>BRAF</i> V600E–Mutated Ameloblastic Fibroma. JCO Precision Oncology, 2019, 3, 1-6.	3.0	2
11	Continuation of adjuvant chemotherapy for osteosarcoma resistant to neoadjuvant treatment. Meaningful action or habit?. Russian Journal of Pediatric Hematology and Oncology, 2019, 6, 48-55.	0.3	0
12	BIFOCAL GERMINOMAS: DOES ONE PLUS ONE ALWAYS EQUAL TWO?. Pediatriia, 2019, 98, 189-195.	0.2	0
13	Leptomeningeal canceromatosis in patient with parameningeal rhabdomyosarcoma. Pediatric Hematology/Oncology and Immunopathology, 2019, 18, 90-98.	0.3	0
14	Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs. Seminars in Cancer Biology, 2018, 53, 110-124.	9.6	101
15	Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human. Oncotarget, 2016, 7, 656-670.	1.8	32
16	A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation. Oncotarget, 2015, 6, 29347-29356.	1.8	52
17	Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow), 2008, 73, 605-618.	1.5	35
18	Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer. Bulletin of Experimental Biology and Medicine, 2003, 135, 478-481.	0.8	22